Fagron Sa Ord (ARSUF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and good morning, everyone. Welcome to Fagron's h one twenty twenty six results webcast. I'm joined today by our CEO, Rafael Padilla, and our CFO, Karin Dejo. Rafael will start by discussing the company's performance and a closer look at regional developments. Kenneth will then walk you through the financial results. We will open the floor for questions at the end of the session. With that, I will hand over to Rafael. Thanks, Ignacio, and good morning all. We're pleased to report a strong performance with revenues reaching €552,000,000 This reflects 3.1% organic growth at CR, 7% when normalizing the GLP-one effect. Growth was driven by brands, Latin America, B and E North America and EMEA. Profitability grew by 12.7% to €107,000,000. The margin of 19.4% reflects an improvement in both EMEA and Latin America and temporary effects in North America Pacific Compounding Services. On M and A, we closed the acquisition of Amber in Singapore and Malaysia, completing five acquisitions across all regions in 2026. We also entered into a collaboration agreement with NutraConect in Asia, which will complement our nutraceutical platform. Integration of earlier announced acquisition remains on track. We have also appointed Amy Jones to lead the North American Pacific region. Finally, we're also reiterating our full year guidance of mid to high single digit growth at CER and an adjusted EBITDA margin of around 20%. Moving on to the regions. In EMEA, performance was led by brands on the back of continuous strategic focus, while essentials remained balanced. We saw, again, strength in compounding services through high demand for key therapies and our focus on operational excellence translated into better availability and procurement savings, supporting both top line and margin ...